These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38565383)

  • 21. Immune-modulating and anti-vascular activities of two xanthenone acetic acid analogues: A comparative study to DMXAA.
    Barbera M; Kettunen MI; Caputo A; Hu DE; Gobbi S; Brindle KM; Carrara M
    Int J Oncol; 2009 Jan; 34(1):273-9. PubMed ID: 19082498
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of α-Mangostin as an Agonist of Human STING.
    Zhang Y; Sun Z; Pei J; Luo Q; Zeng X; Li Q; Yang Z; Quan J
    ChemMedChem; 2018 Oct; 13(19):2057-2064. PubMed ID: 30079976
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Labeling of oxidizable proteins with a photoactivatable analog of the antitumor agent DMXAA: evidence for redox signaling in its mode of action.
    Brauer R; Wang LC; Woon ST; Bridewell DJ; Henare K; Malinger D; Palmer BD; Vogel SN; Kieda C; Tijono SM; Ching LM
    Neoplasia; 2010 Sep; 12(9):755-65. PubMed ID: 20824052
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neutrophil influx and chemokine production during the early phases of the antitumor response to the vascular disrupting agent DMXAA (ASA404).
    Wang LC; Thomsen L; Sutherland R; Reddy CB; Tijono SM; Chen CJ; Angel CE; Dunbar PR; Ching LM
    Neoplasia; 2009 Aug; 11(8):793-803. PubMed ID: 19649209
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The chemotherapeutic agent DMXAA potently and specifically activates the TBK1-IRF-3 signaling axis.
    Roberts ZJ; Goutagny N; Perera PY; Kato H; Kumar H; Kawai T; Akira S; Savan R; van Echo D; Fitzgerald KA; Young HA; Ching LM; Vogel SN
    J Exp Med; 2007 Jul; 204(7):1559-69. PubMed ID: 17562815
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor dose response to the vascular disrupting agent, 5,6-dimethylxanthenone-4-acetic acid, using in vivo magnetic resonance spectroscopy.
    McPhail LD; Chung YL; Madhu B; Clark S; Griffiths JR; Kelland LR; Robinson SP
    Clin Cancer Res; 2005 May; 11(10):3705-13. PubMed ID: 15897567
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy against subcutaneous or intracranial murine GL261 gliomas in relation to the concentration of the vascular-disrupting agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), in the brain and plasma.
    Yung R; Seyfoddin V; Guise C; Tijono S; McGregor A; Connor B; Ching LM
    Cancer Chemother Pharmacol; 2014 Mar; 73(3):639-49. PubMed ID: 24477604
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of human-selective analogues of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Tijono SM; Guo K; Henare K; Palmer BD; Wang LC; Albelda SM; Ching LM
    Br J Cancer; 2013 Apr; 108(6):1306-15. PubMed ID: 23481185
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Consequences of increased vascular permeability induced by treatment of mice with 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and thalidomide.
    Chung F; Liu J; Ching LM; Baguley BC
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):497-502. PubMed ID: 17473922
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anticancer flavonoids are mouse-selective STING agonists.
    Kim S; Li L; Maliga Z; Yin Q; Wu H; Mitchison TJ
    ACS Chem Biol; 2013 Jul; 8(7):1396-401. PubMed ID: 23683494
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice.
    Ching LM; Zwain S; Baguley BC
    Br J Cancer; 2004 Feb; 90(4):906-10. PubMed ID: 14970872
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction of STAT and NFkappaB activation by the antitumor agents 5,6-dimethylxanthenone-4-acetic acid and flavone acetic acid in a murine macrophage cell line.
    Ching LM; Young HA; Eberly K; Yu CR
    Biochem Pharmacol; 1999 Oct; 58(7):1173-81. PubMed ID: 10484075
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy.
    Joseph WR; Cao Z; Mountjoy KG; Marshall ES; Baguley BC; Ching LM
    Cancer Res; 1999 Feb; 59(3):633-8. PubMed ID: 9973211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment with the tumor necrosis factor-alpha-inducing drug 5,6-dimethylxanthenone-4-acetic acid enhances the antitumor activity of the photodynamic therapy of RIF-1 mouse tumors.
    Bellnier DA; Gollnick SO; Camacho SH; Greco WR; Cheney RT
    Cancer Res; 2003 Nov; 63(22):7584-90. PubMed ID: 14633671
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice.
    Ching LM; Goldsmith D; Joseph WR; Körner H; Sedgwick JD; Baguley BC
    Cancer Res; 1999 Jul; 59(14):3304-7. PubMed ID: 10416582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activation of mitogen-activated protein kinases by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) plays an important role in macrophage stimulation.
    Sun J; Wang LC; Fridlender ZG; Kapoor V; Cheng G; Ching LM; Albelda SM
    Biochem Pharmacol; 2011 Nov; 82(9):1175-85. PubMed ID: 21819972
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evidence for the involvement of p38 MAP kinase in the action of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Zhao L; Marshall ES; Kelland LR; Baguley BC
    Invest New Drugs; 2007 Jun; 25(3):271-6. PubMed ID: 17203401
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NF-kappaB-independent induction of endothelial cell apoptosis by the vascular disrupting agent DMXAA.
    Woon ST; Hung SS; Wu DC; Schooltink MA; Sutherland R; Baguley BC; Chen Q; Chamley LW; Ching LM
    Anticancer Res; 2007; 27(1A):327-34. PubMed ID: 17352250
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DMXAA (Vadimezan, ASA404) is a multi-kinase inhibitor targeting VEGFR2 in particular.
    Buchanan CM; Shih JH; Astin JW; Rewcastle GW; Flanagan JU; Crosier PS; Shepherd PR
    Clin Sci (Lond); 2012 May; 122(10):449-57. PubMed ID: 22142330
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): Increased tumor vascular permeability.
    Zhao L; Ching LM; Kestell P; Kelland LR; Baguley BC
    Int J Cancer; 2005 Aug; 116(2):322-6. PubMed ID: 15800918
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.